Top
Main

All Outcomes

Feedback
Home
Show Outline
Top   Main   All Outcomes
Home   COVID-19 treatment studies for Bromhexine  COVID-19 treatment studies for Bromhexine  C19 studies: Bromhexine  Bromhexine   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Loading...
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc
Supplementary Data — Bromhexine for COVID-19: real-time meta analysis of 6 studies
Covid Analysis, December 2022
https://c19early.org/bmeta.html
 
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Ansarin (RCT) 91% 0.09 [0.01-1.59] 24mg death 0/39 5/39 Improvement, RR [CI] Dose (1d) Treatment Control Ansarin (RCT) 89% 0.11 [0.01-0.84] 24mg ventilation 1/39 9/39 Ansarin (RCT) 82% 0.18 [0.04-0.77] 24mg ICU 2/39 11/39 Li (RCT) 75% 0.25 [0.05-1.35] 96mg no disch. 2/12 4/6 Li (RCT) 50% 0.50 [0.09-2.73] 96mg oxygen 2/12 2/6 Mareev (RCT) 11% 0.89 [0.65-1.22] 32mg no recov. 33 (n) 33 (n) CT​1 Mareev (RCT) 39% 0.61 [0.14-0.97] 32mg no disch. 14/24 20/21 CT​1 Mareev (RCT) 8% 0.92 [0.77-1.09] 32mg hosp. time 33 (n) 33 (n) CT​1 Mareev (RCT) 87% 0.13 [0.01-2.25] 32mg viral+ 0/17 3/13 CT​1 Tolouian (RCT) 76% 0.24 [0.01-8.03] 32mg death 48 (n) 52 (n) Tolouian (RCT) 76% 0.24 [0.01-7.69] 32mg no improv. 48 (n) 52 (n) Tolouian (RCT) -75% 1.75 [1.13-2.71] 32mg viral+ 29/48 18/52 Mikhaylov (RCT) 80% 0.20 [0.01-3.97] 24mg hosp. 0/25 2/25 Mikhaylov (RCT) 91% 0.09 [0.01-1.56] 24mg symp. case 0/25 5/25 Mikhaylov (RCT) 71% 0.29 [0.07-1.24] 24mg viral+ 2/25 7/25 Tolouian (DB RCT) 33% 0.67 [0.04-10.5] 24mg death 0/187 1/185 Tolouian (DB RCT) 70% 0.30 [0.05-1.78] 24mg hosp. 1/187 6/185 Tolouian (DB RCT) 53% 0.47 [0.25-0.87] 24mg symp. case 16/187 34/185 Tolouian (DB RCT) 50% 0.50 [0.24-0.99] 24mg cases 13/187 26/185 Bromhexine COVID-19 outcomes c19early.org/b Dec 2022 1 CT: study uses combined treatment Favors bromhexine Favors control
Figure S1. All outcomes.
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit